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Systemic sclerosis is a fascinating, although uncommon condition. However, ﬁbrosing alveolitis in
systemic sclerosis patients is common and is associated with signiﬁcant morbidity and mortality.
Investigations assist, not only with diagnosis, but also with assessment of disease severity and assess-
ment of the likelihood of disease progression, thus helping to identify those requiring closer medical
supervision. Treatment of ﬁbrosing alveolitis in systemic sclerosis is complex, as the risks of some
therapies may outweigh the potential beneﬁts, and for those with advanced disease there is a lack of
donor organs available for transplantation. Great strides continue to be made in unravelling the
mysteries of the immunopathogenesis of ﬁbrosing alveolitis in systemic sclerosis, and this should
eventually lead to the development of more rational and targeted pharmacological therapies.
 2009 Elsevier Ltd. All rights reserved.Educational aims
 To discuss the clinical presentation of FASSc.
 To discuss the physiology of FASSc and testing for the disorder.
 To outline radiology of FASSc in detecting subtle abnormalities.
 Look into further treatments of the disorder.1. Introduction
Systemic sclerosis (SSc) or scleroderma is a connective tissue
disorder (CTD) characterised by skin thickening, which may be
accompanied by involvement of internal organs. SSc may affect the
lungs by ﬁbrosing alveolitis (FA or FASSc); pulmonary hypertension
(PHT); lung cancer; pleural disease; aspiration pneumonitis;
extrathoracic restriction through a ‘‘cuirasse effect’’; diffuse alve-
olar damage and pulmonary haemorrhage.
The term systemic sclerosis is derived fromGreek (sclero¼ hard,
derma¼ skin). SSc has a female preponderance of 4:1, which in the
childbearing years may be as high as 15:1, with a peak age of
incidence of 30–50 years.1 On the basis of the distribution of skin
involvement SSc is divided into limited (lSSc) and diffuse (dSSc)
cutaneous subtypes,2 with the limited form not extending proximal
to either the elbows or the knees, although facial skin thickening
occurs in both. The limited form includes the CREST syndrome
(Calcinosis, Raynaud’s phenomenon, oEsophageal dysmotility,
Sclerodactyly, Telangiectasia). This division into subtypes has.ukimportant connotations with respect to autoantibody proﬁle and
spectrum of internal organ involvement.2. Clinical features of FASSc
Assessment of exercise tolerance on both ﬂat and stairs is
important, as is whether the patient is limited by breathlessness or
because of some other symptom (s) e.g. joint pains. Joint pains may
mask respiratory symptoms, as the patient cannot exercise sufﬁ-
ciently to precipitate breathlessness.
Dyspnoea is a common symptom of FASSc, initially exertional
but with disease progression the patient may become breathless at
rest. Cough in FASSc may be dry or productive.3 Haemoptysis is
uncommon in FASSc and should alert the clinician to the possibility
of scar malignancy, which may occur in up to 3% of SSc patients and
is associated with the presence of FASSc.4 Haemoptysis can also
occur from endobronchial telangiectasia.
The commonest physical ﬁnding in FASSc is bilateral basal
crackles.5 Digital clubbing is uncommon, possibly as a result of
impaired peripheral blood ﬂow in SSc and skin tightening.6
Features of pulmonary hypertensionmay be present (raised jugular
venous pressure [JVP], loud pulmonary 2nd heart sound [P2], pedal
oedema and a right ventricular/parasternal heave). Pulmonary
arterial hypertension (PAH) has a prevalence of 21% in lSSc and 26%
in dSSc.7 Whilst this may be hypoxaemia-induced, due to disease
severity, it may well be because of pulmonary vascular disease
(PVD), per se, particularly in lSSc (10% of lSSc cases)8 and if the
patient is anti-centromere antibody positive (vide infra). The
prevalence of isolated PAH in patients with dSSc is 2%.8 Further-
more, the prevalence of PAH appears to be no different in SSc
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severity of cutaneous and pulmonary involvement do not correlate
very well but FASSc is more common in dSSc, and PHT in lSSc.10
3. Autoantibodies in SSc
Anti-nuclear antibodies (ANA) are autoantibodies directed
against structures within cell nuclei. They may be detected at
different dilutions, with the more CTD-speciﬁc values (>1:100)
being found in <10% of the normal population11 with a nucleolar
pattern suggesting SSc.1
Approximately half of patients with SSc carry an autoantibody,
either anti-topoisomerase-I (26%) or anti-centromere antibody
(ACA [22%]), with no patient carrying both autoantibodies.12 Anti-
topoisomerase-I is associated with diffuse cutaneous disease and
FASSc12–14 whereas ACA is associated with limited cutaneous
disease and pulmonary hypertension.13,14
4. Physiology
4.1. Pulmonary function tests
The classical PFT abnormalities seen in FASSc include a *restric-
tive ventilatory defect associated with a depressed gas transfer
(TLCO)3,31. Lung volumes may give an indication of ﬁbrosis severity
but with co-existent emphysema, they may be relatively normal
because of gas trapping. TLCO can be up to 20% less (on % predicted)
than lung volumes but further, more disparate, loss of TLCO raises
the possibility of co-existent pulmonary vascular disease (PVD).
*Restrictive ventilatory defect is characterised by a reduction
total lung capacity (TLC), forced expiratory volume in 1 s *(FEV1)
and forced vital capacity (FVC) with an elevated FEV1: FVC
ratio.32,33
A single PFT result gives a snapshot of disease extent but, in
order to get a view of disease activity, serial testing is required as
subtle downward trends may be revealed, which may reﬂect
disease activity. Decreases of <10% may be reassessed at a 3-month
interval to see if this is the start of a trend downwards. Wells et al.34
showed that the major determinant of functional impairment is the
degree of FA on high resolution computed tomography (HRCT), and
that this is best reﬂected in the percent predicted TLCO.
4.2. Six minute walk test
The sixminutewalk test (6MWT) is highly reproducible in FASSc
but its use in FASSc is limited by its weak correlation with % pre-
dicted FVC and Borg dyspnoea index and a non-correlation with %
predicted gas transfer.35 However, this study used the 6MWT
outcome measure as distance walked rather than oxygen desatu-
ration. Others have shown that oxygen desaturation of >4% is
associated with % predicted FVC< 80%.36
5. Radiology
5.1. Chest radiography
The chest radiograph (CXR) in FASSc is abnormal in up to 80% of
cases (i.e. it can appear normal)37,38 and ﬁbrosis on the CXR may
predate the onset of scleroderma.39 Typical CXR features include
a predominantly bibasal reticulonodular pattern. Cystic areas may
form within ﬁbrotic areas giving a ‘‘honeycomb’’ appearance.
Fibrosis may result in elevation of the hemidiaphragms and
decreased lung volumes. Pneumothoraces may result from rupture
of subpleural cysts.40 Oesophageal dilatation may be seen on CXRbut is better visualised with HRCT and has been found in 80% of
asymptomatic cases on HRCT.41
Using the CXR to assess disease activity may lead to delays in
detecting clinically signiﬁcant disease as it is less sensitive than
other methods such as CT for detecting subtle abnormalities.
5.2. High resolution computed tomography
HRCT is a major advance in the management of FASSc and may
obviate the need for conﬁrmatory histology.
Each CT image is a 2-dimensional image of the thorax in cross-
section and is a matrix of picture elements (pixels), each of which is
a 3-dimensional entity (voxel) with volume.42 The thicker the
sections, the thicker the voxel volume and thus the greater the
chance of including differing densities, which are then averaged to
give the voxel a density on CT. As the ﬁnal CT image represents all
the voxels, thicker sections will have a greater averaging of each
voxel, the so-called ‘‘partial volume effect’’.42 Thinner sections have
less density averaging and are therefore better suited for interstitial
imaging.
With modern scanners the effective radiation dose for HRCT is
the equivalent of 7-14 CXR, depending on whether 10 or 20 mm
interspaces are employed43. Worldwide annual background radia-
tion is 1–10 mSv with an average of 2.4 mSv44 i.e.w50 CXR worth
of radiation per annum (1 CXR¼ 50 mSv). Due to spacing of thin
sections, it is not possible to comprehensively evaluate the entire
lung parenchyma and, therefore small lesions may be missed. This
can be overcome by simultaneous contiguous thick section CT
images being taken where necessary.
In SSc patients with a normal CXR, 29% of cases of SSc will have
an abnormal thoracic HRCT.45 When CXR and HRCT are used in SSc
to evaluate dyspnoea and/or abnormal pulmonary function tests,
the CXR is abnormal in 59% cases whereas the HRCT is abnormal in
88% cases.46 Overall, HRCT can detect pulmonary abnormalities in
60–90% SSc patients.37,47
HRCT may detect co-existent pathologies, which can help
explain disparate loss of TLCO relative to lung volumes, for example
FASSc and co-existent emphysema. HRCT may obviate the need for
biopsy because of a pathognomic HRCT appearance and can direct
the surgeon to the most appropriate site for biopsy.
Several HRCT abnormalities may be seen in FASSc48: -
 Ground glass (GG) opaciﬁcation.
 Reticular pattern (ﬁne through to honeycombing).
 Subpleural distribution (especially honeycombing).
 Traction bronchiolectasis.
 Cysts of 1–3 cm diameter.
 Various lines – septal, subpleural, and long (non-septal)
parenchymal lines.
 Micronodulation (especially subpleural but also intralobular).
Other non-parenchymal abnormalities may be seen on thoracic
HRCT in SSc patients including: -
 Mediastinal lymphadenopathy.49
 Pulmonary arterial hypertension.50
 Lung cancer.37
 Aspiration pneumonia.51
Traditionally, GG change on HRCT has been thought to correlate
with cellular inﬂammatory inﬁltrates and reticular shadowing with
ﬁbrosis. GG opaciﬁcation arises from displacement of air from
airspaces, which can occur because of ﬂuid, ﬁbrosis or during
expiration. Unlike the CXR, GG on HRCT does not obscure the
pulmonary vasculature.52,53 However, GG may represent ﬁne
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reticular pattern. Clues to this include traction bronchiectasis or
bronchiolectasis.
HRCT has been used as a predictor of FASSc histology. Wells
et al.56 compared HRCT appearances in 12 FASSc patients with their
open lung biopsy appearances. Two grading systemswere used, one
for HRCT appearances and one for histological appearances. They
found a signiﬁcant (p< 0.04) association between grade 4 HRCT
appearance (predominantly reticular pattern) and a ﬁbrotic histo-
logical appearance, and a signiﬁcant association between grade 3
HRCT appearance (amorphous parenchymal opaciﬁcation equal in
extent to reticulation) and an inﬂammatory histological appearance.
Subsequently, the same authors examined the use of HRCT to
predict prognosis and response to treatment in FASSc. They
reviewed 66 FASSc patients, of whom 36 had conﬁrmatory
histology from open lung biopsy.57 The HRCT appearances were
divided into 3 grades (different from those in the earlier study
above): grade 1 [GG> reticular pattern]; grade 2 [GG¼ reticular
pattern]; grade 3 [GG< reticular pattern]. They found that, whilst
percent predicted FVCwas predictive of survival in FASSc (p< 0.01),
the HRCT appearance did not predict 4-year survival (p¼ 0.26).
They also found the duration of dyspnoea in FASSc at the time of
HRCT was longer for grade 3 than grade 2 appearances (p< 0.05).
With treatment, there was a non-signiﬁcant (p¼ 0.10) improve-
ment in PFT at 1 year in 5/11 (45%) grade 2 and 2/13 (15%) grade 3
FASSc patients. PFT deterioration was commonest in FASSc patients
with grade 3 HRCT appearances, although this did not reach
statistical signiﬁcance (p¼ 0.14). Of the 66 patients, 13 had received
no treatment prior to HRCT examination. An analysis of this
subpopulation revealed that the 3 patients who improved, as
judged by PFT, all had grade 2 HRCT appearances initially, although
this failed to reach statistical signiﬁcance (p¼ 0.12).
5.3. DTPA scanning
99mTc-diethylenetriaminepentaacetic acid (DTPA) scanning
assesses pulmonary epithelial permeability and hence alveolar-
capillary integrity. DTPA is administered by nebuliser and the rate
of diffusion from alveoli to the vascular space is measured with
a gamma camera. The quicker the DTPA clearance, the greater the
pulmonary epithelial permeability, which is thought to be indica-
tive of inﬂammation. In normal humans, half-time clearance from
each lung is approximately 40 min.58 DTPA clearance is greatly
increased in cigarette smokers,59 as a result of surfactant
dysfunction.59
DTPA in SSc patients may detect pulmonary involvement in SSc
at an earlier stage, even in the presence of normal chest radiology
(CXR and HRCT).60 DTPA clearance has been assessed in SSc
patients with no respiratory symptoms and a normal CXR, and was
rapid in 6/16 (38%) patients but, of these, 5/6 (83%) had early FASSc
on HRCT.61
Normal DTPA (>40 min) predicts stable disease but rapid DTPA
(<40 min) is not synonymous with disease progression.62 If DTPA is
repeatedat12months then2 subgroups emerge: onewith sustained
fast DTPA clearancewho have increased risk of disease progression;
and one who revert to normal DTPA clearance, which is associated
with a ‘‘sustained improvement in respiratory function indices’’.53
6. Bronchoalveolar lavage
Attempts have been made to standardise bronchoalveolar
lavage (BAL)63 but there remains differing deﬁnitions of what
constitutes ‘‘alveolitis’’ in FASSc.64–66
Emerging evidence suggests that the type of granulocytic BAL is
important in determining prognosis. Several studies have used BALneutrophilia as an index of disease activity.23,64,65 However, this has
been challenged by evidence that BAL neutrophilia is no different
between FASSc and the more progressive disease, idiopathic
pulmonary ﬁbrosis (IPF), once disease extent and functional
impairment have been taken into account.67 In this study, BAL
neutrophilia was strongly linked to the extent of reticular ﬁbrotic
abnormalities on HRCT.67 It is therefore likely that BAL neutrophilia
is merely a reﬂection of the extent of ﬁbrosis rather than an
implicitly more aggressive phenotype.
However, BAL eosinophilia may have predictive value, inde-
pendent of any associationwith disease extent at the time of BAL. In
contrast to BAL neutrophilia, BAL eosinophilia is higher in IPF
compared to FASSc, when disease extent and functional impair-
ment have been taken into account.67 BAL eosinophilia is associated
with signiﬁcantly higher mortality in FASSc patients with biopsy
proven NSIP.68
It has therefore been suggested that BAL neutrophilia occurs in
more extensive disease, whereas BAL eosinophilia denotes intrin-
sically more progressive disease, independent of disease extent.69
7. Lung biopsy
Historically, biopsy and histology have been considered the gold
standard in the diagnosis of DPLD, although this is now being
challenged with the suggestion that it is the most ‘‘argentiferous of
the silver standards of clinical, radiological and histopathological
evaluation’’.70
FASSc should not be diagnosed by bronchoscopic biopsy as
specimens are small and there is great scope for sampling error.71,72
Surgical lung biopsy provides larger biopsy specimens, which are
more likely to yield a diagnosis. Open lung biopsy (OLB) has
a greater yield than transbronchial biopsy (94% vs 72%)72 but is
generally not repeatable, which makes its use as a measure of
disease activity unacceptable.
Video-assisted thoracoscopic surgery is now frequently used for
surgical lung biopsy in diffuse lung diseases and has a similar safety
and diagnostic efﬁcacy but a reduced operative and hospital stay.73
8. Treatment of FASSc
Studies have failed to show any convincing beneﬁt when FASSc
patients are treated with corticosteroids15,16. Additionally, high
dose corticosteroids (>20 mg/day prednisolone) are associated
with renal crisis, independent of blood pressure.17 High dose
corticosteroids are therefore not recommended unless there is
accelerated disease, in which case the kidneys should be ‘‘pro-
tected’’ with Iloprost, which may ameliorate renal vasospasm.18
Early studies of cyclophosphamide have shown variable beneﬁts
on pulmonary function and survival,19–23 although the consensus
opinion is that cyclophosphamide is the best drug for FASSc.24
Intravenous cyclophosphamide can result in partial regression of
FASSc, as judged by serial PFT25,26 or serial HRCT.25,27
More recently two randomised controlled trials of intravenous
cyclophosphamide vs placebo have shown a trend towards stabi-
lisation of pulmonary function in a subset of patients28 and a small
(2.5% predicted) better forced vital capacity (FVC).29
Uncontrolled retrospective reviews have shown that azathio-
prine may help stabilise pulmonary function and improve symp-
toms in SSc.30
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1. In systemic sclerosis, which autoantibody is most associated
with pulmonary arterial hypertension?
a. Anti-centromere
b. Anti-topoisomerase I
c. Anti-nuclear antibody
d. Anti-dsDNA
e. Anti-Ro
2. A patient with systemic sclerosis has normal spirometric and
static lung volumes but a reduced gas transfer. What is the
most likely explanation?
a. Pulmonary ﬁbrosis
b. Cuirasse effect of thoracic skin tightening
c. Pulmonary vasculopathy
d. Pleural effusion
e. Pulmonary haemorrhage
3. Which one of the following is true of DTPA scanning in
ﬁbrosing alveolitis due to systemic sclerosis (FASSc)?
a. Clearance is reduced in cigarette smokers
b. Fast clearance indicates imminent disease progression
c. Will be normal if high resolution CT (HRCT) scan is normal
d. May be fast even in the absence of respiratory symptoms
e. Must be administered by slow intravenous injection
4. Which one of the following is true of bronchoalveolar lavage
(BAL) in ﬁbrosing alveolitis due to systemic sclerosis (FASSc)?
a. BAL is contra-indicated if lung function abnormal
b. BAL neutrophilia indicates disease activity
c. BAL eosinophilia is associated with a higher mortality
d. BAL eosinophilia is dependent upon disease extent on HRCT
e. BAL eosinophilia is higher in FASSc than idiopathic
pulmonary ﬁbrosis, once adjusted for disease extent and
functional impairment
5. Concerning the treatment of FASSc, which one of the following
is true?
a. High dose corticosteroids are needed if co-existent renal
disease
b. Intravenous cyclophosphamide may stabilize lung function
c. Corticosteroids are contra-indicated if patient on iloprost
d. Intravenous cyclophosphamide should only be used in
diffuse systemic sclerosis
e. Randomized controlled trials have proven azathioprine to
be the drug of choiceReferences
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